89bio Analyst Ratings
BenzingaApr 22 18:11
B of A Securities Assumes 89bio at Buy, Announces Price Target of $30
BenzingaApr 22 18:14
89bio Analyst Ratings
BenzingaApr 5 21:21
Buy Rating Affirmed for 89bio's Pegozafermin: A Promising NASH Treatment With Strong Regulatory Endorsements
TipRanksMar 29 15:09
89bio Analyst Ratings
BenzingaMar 28 01:51
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
TipRanksMar 28 00:30
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)
TipRanksMar 15 17:20
Analysts' Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
TipRanksMar 13 22:00
89bio Analyst Ratings
BenzingaMar 13 21:49
89bio Analyst Ratings
BenzingaMar 7 23:58
Buy Rating Reaffirmed for 89bio With Potential Market Edge in Fibrosis and Metabolic Diseases
TipRanksMar 7 12:19
89bio Analyst Ratings
BenzingaMar 7 02:56
Analysts' Top Healthcare Picks: 89bio (ETNB), UnitedHealth (UNH)
TipRanksMar 5 08:21
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Vicarious Surgical (RBOT) and 89bio (ETNB)
TipRanksMar 5 08:02
89bio Analyst Ratings
BenzingaMar 4 23:13
RBC Capital Sticks to Their Hold Rating for 89bio (ETNB)
TipRanksMar 1 20:27
89bio Analyst Ratings
BenzingaMar 1 20:18
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk
MT NewswiresMar 1 20:02
RBC Capital Downgrades 89bio to Sector Perform, Announces $15 Price Target
BenzingaJan 12 20:16
89bio Analyst Ratings
BenzingaJan 12 20:15
No Data
No Data